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Patients were retrospectively staged according to the
Ann Arbor staging system. The work-up for staging
included complete physical examination, complete blood
count, chemistry panel, computerized tomographic scan
of neck, chest and abdomen, whole body bone scan,
gallium scan, PET scan and bone marrow aspiration and
biopsy. A skeletal magnetic resonance image was
obtained in five cases. CT scan was also performed in
the abdomino-pelvic area in 13 cases, the chest in 13,
the neck in 13 and the brain in 10. Whole body bone
scan was done in 13 cases and gallium scan was done
in 10. Bone marrow study was done in 15 cases.
Response to treatment was recorded as complete
remission (CR), partial remission (PR) or no response
(NR). CR was defined as a complete disappearance of
all clinical evidence of lymphoma by physical examination
and imaging studies; PR as a reduction of more than
50% in the sum of the products of perpendicular
diameters of all measurable masses with no new lesion;
NR as stable or progressive disease except CR or PR.
The overall survival time was calculated from the date
of diagnosis until the date of the last follow-up or death.
The disease-free survival time was calculated from the
date of documentation of CR until the date of the last
follow-up in a disease-free state. Survival curves were
calculated according to the Kaplan-Meier method and
comparison of survival was performed using the log-rank
test.
RESULTS
Age and sex
Of the 16 cases studied, ten were male and six were
female with a ratio of 1:0.6 (Table 1). The median age
was 44 years (range, 1∼71 years).
Clinical manifestation
The most common presenting complaints were bone
pain (Table 2). Three cases presented with B symptoms.
Neurologic symptom (voiding difficulty) was present in
two cases. Pathologic fracture was present in one case.
Site of involvement
PLB involved a wide variety of sites (Figure 1). Femur
and thoracic spine, which appeared in 6 cases, were
the most commonly involved sites at diagnosis. The
PLB most often presented in the irregular bone (T spine,
femur, L spine, ileum and C spine in order).
Table 1. Clinical, histological and therapeutic para-
meters of the patients
Number of
cases
Percentage
(%)
Sex
Male 10 62
Female 6 37
Age
> 60 years 25
≤ 60 years 12 75
Stage
I 2 12
II 3 19
III 0 0
IV 8 50
Uncertain 3 19
Histology (WHO classification)
Diffuse follicular center 1 6
T cell rich B cell 1 6
Diffuse large cell 10 62
Precursor B lymphoblastic
leukemia/lymphoma 1 6
Hodgkin's disease (mixed cellularity) 1 6
Peripheral T cell, not
otherwise specified 1 6
Unspecified 1 6
Cell type
T cell 1 6
B cell 14 88
Unspecified 1 6
International Prognostic Index score
Low (0-1) 4 25
Low intermediate (2) 5 31
High intermediate (3) 0 0
High (4-5) 4 25
Unknown 3 18
Therapy
Chemotherapy only 3 18
Radiotherapy and chemotherapy 8 50
Radiotherapy only 0 0
Surgery, radiotherapy
and chemotherapy 2 12
No treatment 3 18
Response to therapy
Complete remission 7 53
Partial remission 3 23
No response 3 23
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Histological classification
Using the WHO classification, most of the cases were
in the diffuse large B-cell category (Table 1). One case
was classified as Hodgkin's disease. T-cell immuno-
phenotype was noted in one case.
Clinical staging
The clinical stage of lymphoma was IEA in two cases,
IIEA in three cases, IVEA in five cases and IVEB in
three cases (Table 1). Stage II diseases had lymph node
involvement near the site of the bone localization.
Response to treatment, survival and prognostic factors
Among treated thirteen cases, three cases were
treated with only chemotherapy, eight cases with
radiotherapy and chemotherapy and two cases with
surgery, radiotherapy and chemotherapy. Radiotherapy
was delivered by either linear accelerator or cobalt-60.
Radiation dose ranged from 30 to 60 Gy with a median
dose of 45 Gy.
Seven cases (54%) of all treated cases achieved CR,
three cases (23%) PR and three cases (23%) NR (Table
1). The median follow-up period was 28 months (range,
2∼108 months). The median disease-free survival of
seven cases which achieved CR was not reached
(range, 15∼97 months) and five-year disease-free survival
rate was 85%. The median overall survival of all treated
cases was not reached (range, 2∼108 months) and five-
year overall survival rate was 54% (Figure 2).
There was no significant difference of overall survival
according to stage, performance, LDH and IPI (International
Prognostic Index) scores (Figure 3).
Table 2. Presenting signs and symptoms
Symptom and sign Number of cases
Pain of bone 10
Mass 3
Fever 2
Voiding difficulty 2
Fracture 1
Swelling 1
Figure 1. Site of involvement. The sites of involvement
are included in the figure; femur 6 cases; thoracic spine 6
cases; lumbar spine 5 cases; skull 4 cases; ileum 4 cases;
rib 2 cases; sacrum 2 cases; scapula 2 cases; sternum 2
cases; clavicle 1 case; humerus 1 case; mandible 1 case;
cervical spine 1 case; tibia 1 case; ulna 1 case
Figure 2. Overall survival (months) of treated patients
(N=13)
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DISCUSSION
PLB (previously called reticulum cell sarcoma) is a rare
lymphoid malignancy and accounts for approximately
3∼15% of all extranodal non-Hodgkin's lymphoma2, 4).
The true incidence of PLB is difficult to assess, as the
site of origin is unclear in patients with disseminated
lymphoma and bony involvement. In Korea, PLB
accounts for about 1.3∼1.6% of all malignant lymphoma,
1.4∼1.8% of non-Hodgkin's lymphoma and 3.7% of
extranodal non-Hodgkin's lymphoma5, 6), while there
was no report of primary lymphoma of bone in
Hodgkin's disease. Song et al.7) reported the first case
of primary bone lymphoma associated with acquired
immunodeficiency syndrome in Korea. During this study,
primary lymphoma of bone accounted for 1% (16/1,600
cases) of malignant lymphoma, 1% (15/1,448 cases) of
non-Hodgkin's lymphoma and 0.65% (1/152 cases) of
Hodgkin's disease in Severance Hospital.
In general, lymphoma presenting in bone is a sign of
disseminated (stageIV) disease. But, occasionally, it may
be a true solitary lesion, defined as involvement of single
extralymphatic organ or site (stageIE)8-10). Reimer et al.8)
reported that only one of twelve presenting with bone
lymphomas had a true solitary lesion. Sweet et al.9)
reported that 50% of so called solitary lesions were
associated with disease elsewhere. He emphasized
that all cases with a presumed solitary lymphoma of
bone should undergo a thorough evaluation for other
involvement. Many studies on primary lymphoma of bone
excluded patients with stage IV disease in an effort to
eliminate malignancies in which bone involvement is
secondary11, 12). In our study, three cases (19%) presented
with simultaneous bone and nodal or soft tissue
involvement and nine cases (56%) presented with
multifocal bone involvement.
Figure 3. Comparison of overall survival according to stage (stageI, II vs. stageIV, p=0.392), performance (ECOG 0, 1 vs. 2-4,
p=0.1974), LDH (normal vs. abnormal, p=0.3235) and IPI score (0-2 vs. 3-5, p=0.0537)
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The peak incidence appears to be in the fifth decade,
with a slight preponderance of males over females13). In
our study, age and sex distribution were similar to other
studies (median age at presentation was 44 years and
there was a male predominance with a male to female
ratio of 1:06). In most of our cases, the initial symptoms
were localized bone pain or swelling, as reported by
others14). Pathologic fractures are possible complication of
bone lymphoma. Kenan et al.15) reported 6 cases (30%)
with pathologic fracture among 20 cases of primary
skeletal lymphoma. In our study there was one case
(6.3%) with pathologic fracture.
Malignant lymphoma of bone involved a wide variety of
sites as reported by others15). The most prevalent site in
this studies was the irregular bone. In one study, tumor
localization within the pelvis or vertebra was associated
with a worse prognosis16), but in our study tumor loca-
lization was not a significant prognostic factor.
Although the histomorphologic features of malignant
lymphomas of lymph nodes have been extensively studied
in relation to prognosis, there are relatively few similar
studies of lymphomas of bone16, 17). Most of the lesions
were in the diffuse large B-cell category, as other
studies16). Some study revealed that histologic subgroup
has no prognostic significance15), but in one study,
immunoblastic lymphoma had a worse prognosis than
other large B cell lymphoma subtypes10). In our study,
there was no significant difference in overall survival
between histologic grades (data was not shown).
The stage of the disease is the single most important
prognostic indicator in malignant lymphoma of bone10, 18, 19).
In this study, the 5-year overall survival rate of stage I or
II disease was 80% and the 5-year overall survival rate
of stage IV disease was 45%. But there was no
significant difference between the two groups (p=0.3920).
Treatment of bone lymphoma is based on the extent
of disease. Stage IE lesions have traditionally been treated
with radiotherapy, with which the cure rate is reported up
to 90%. Some studies suggested that the outcomes are
superior for patients with primary bone lymphoma who
are treated with combined modality therapy versus
single modality therapy20), while other studies did not
detect any difference between treatments21). In this study,
all treated patients received systemic chemotherapy.
And ten cases were treated with combined modality
therapy. Of ten cases who were treated with combined
modality therapy, six achieved complete remission, but
of three cases who were treated with chemotherapy
alone one achieved complete remission. But there was
no significant difference in overall survival between
treatment modalities (p=0.66).
The overall survival of PLB was reported variably by
many authors. Bacci et al.22) reported on 30 cases
treated for localized PLB over a 10-year period, with
overall disease-free survival rate of 88% at a mean
follow-up period of 87 months. Mendenhall et al.18)
reported their experience with 11 cases who received
combined modality therapy, nine cases who received
local radiotherapy alone and one case who received
chemotherapy alone. In the study, five-year overall
survival rate was 56% and no treatment modality
demonstrated any advantage. Susnerwala et al.23) reported
on 39 cases treated for PLB over a 10-year period. In
their report, overall and disease-free survival rates at 60
months were 66% and 56%, respectively. Barr et al.24)
reported on 17 cases with PLB, overall survival of which
was 79%. Heyning et al.10) reported on 60 cases with
PLB which included the disseminated (stageIV) disease.
In their report, the five-year overall survival rate was
61%.
The median overall survival in our study was not
reached after median follow-up period of 28 months.
And our study revealed 54% of five-year overall
survival rate. The overall survival of our study was
similar or inferior to other studies10, 18, 22-24). Considering
that our study included multifocal skeletal lymphomas,
the overall survival was considered to be similar to other
studies10, 18, 22-24). More promising therapeutic strategies
are needed for survival improvement on more accu-
mulated cases.
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